[18F]FDG uptake of bone marrow on PET/CT for predicting distant recurrence in breast cancer patients after surgical resection

EJNMMI Research

Table 2 Relationship of recurrence pattern with [¹⁸F]FDG PET/CT parameters of primary breast cancer and BM

		No recurrence (n = 309)	Locoregional recurrence (n = 16)	Distant recurrence (n = 20)	p value
Maximum SUV	Median	3.69	7.21	9.20	< 0.001*
Maximum SUV	Range	0.90–37.90	2.36–17.96	1.95–17.47
MTV	Median	0.78	5.26	10.00	< 0.001*
MTV	Range	0.0–234.50	0.0–235.30	0.0–528.58
TLG	Median	2.33	25.90	42.43	< 0.001*
TLG	Range	0.0–1674.52	0.0–1682.09	0.0–3311.99
BM SUV	Median	1.60	1.64	1.75	0.090
BM SUV	Range	0.62–2.73	1.27–2.45	1.11–1.96
BLR	Median	0.75	0.80	0.98	< 0.001^†
BLR	Range	0.35–1.54	0.51–1.16	0.50–1.33

SUV standardized uptake value, MTV metabolic tumor volume, TLG total lesion glycolysis, BM bone marrow, BLR bone marrow-to-liver uptake ratio
*On post hoc analysis, patients with locoregional and distant recurrence had significantly higher values than those with no recurrence (p < 0.05). However, no significant difference was shown between patients with locoregional recurrence and those with distant recurrence (p > 0.05)
†On post hoc analysis, patients with distant recurrence showed significantly higher value than those with no recurrence and locoregional recurrence (p < 0.05). However, no significant difference was shown between patients with no recurrence and those with locoregional recurrence (p > 0.05)